- Details
- Oliver Sartor speaks with Russ Pachynski, Chris Maher, and Aadel Chaudhuri about their novel biomarker study in advanced prostate cancer. The discussion centers on their development of a cell-free DNA assay that examines both AR gene and enhancer alterations in mCRPC patients, showing significant prognostic value for treatment outcomes. Dr. Chaudhuri presents their discovery of a stemness signatur...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Bertrand Tombal challenges traditional salvage radiation approaches in high-risk EMBARK patients. Based on trial results showing enzalutamide's survival benefits, he advocates shifting from radiation-first to systemic ARTA treatment, with radiation as a secondary consideration. Biographies: Bertrand Tombal, MD, PhD, Chairman of the...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Daniel Spratt examines systemic therapy in post-operative biochemical recurrence, challenging universal hormone therapy with salvage radiation. He demonstrates varying benefits based on PSA levels and emphasizes treatment personalization using genomic classifiers and MMAI models. Biographies: Daniel Spratt, MD, Chair and Professor...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Derya Tilki leads a panel with Drs Tombal, Spratt, and Alicja Jereczek-Fossa examining salvage radiation timing, EMBARK trial interpretation, and treatment decision factors in biochemically recurrent prostate cancer, balancing PSA levels and patient-specific characteristics. Biographies: Derya Tilki, MD, Associate Professor of Urol...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Paul Nguyen analyzes treatment approaches for post-prostatectomy and salvage radiation biochemical recurrence, comparing SBRT versus whole pelvis radiation for lymph node metastases. He examines current evidence and ongoing trials informing treatment decisions. Biographies: Paul L. Nguyen, MD, MBA, FASTRO, Baldwin-Politi Distinguis...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Matthew Smith presents an overview of prognostic and predictive biomarkers in metastatic castration-sensitive prostate cancer, examining established factors like disease patterns and volume while highlighting the Decipher score's prognostic value. Biographies: Matthew Smith, MD, PhD, Oncologist, Professor of Medicine, Harvard Medic...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Robert Jones discusses the role of combination therapy in low-volume metastatic prostate cancer, examining evidence from PEACE-1 and meta-analyses that suggest potential benefits of triplet therapy (radiotherapy + ARPI + ADT) over doublet options despite not reaching statistical significance. Biographies: Robert Jones, PhD, Profess...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Oliver Sartor discusses the management of synchronous, low-volume, metastatic hormone-sensitive prostate cancer. The presentation analyzes data from major trials like PEACE-1 and ARASENS while addressing the benefits of prostate radiation and acknowledging the complexity of real-world treatment decisions. Biographies: Oliver Sartor...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Nicholas James presents an analysis of triplet therapy in prostate cancer treatment, examining evidence from the PEACE-1, ARASENS, and ENZAMET trials. Through network meta-analysis, he explores the comparative effectiveness of different treatment combinations and proposes a framework based on disease characteristics. Biographies: N...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Sandy Srinivas examines the role of radiation therapy to the primary tumor in metastatic prostate cancer. The presentation questions whether overall survival should be the sole metric for evaluating interventions. Biographies: Sandy Srinivas, MD, Oncologist, Professor of Medicine (Oncology), Stanford University, Palo Alto, CA Relat...
|
